CSCC Webinar Lectureship on Cardiovascular Disease
Thursday February 6, 2020
11:00 PT / 12:00 MT / 13:00 CT / 14:00 ET / 15:00 AT / 15:30 NL
Sponsored by
Inflammatory Biomarkers and Anti-Cytokine Therapy for Atherosclerosis: Update 2020
Speaker:
Paul M. Ridker, MD
Eugene Braunwald Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital
There is no charge to attend this lecture but it is necessary to register (scroll down).
Inflammation is a major determinant of atheroclerosis and inflammatory biomarkers such as hsDRP and IL-6 are as strong predictorrs of vascular disease as are LDL cholesterol and blood pressure. Yet until recently there has been no proof of concept that lowering inflammation could lower the risks of these life-threatening disorders. The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that, in the absence of lipid lowering or blood pressure reduction, inhibition of IL-1-beta and consequent lowering of IL-6 and hsCRP results in statistically significant benefits for major cardiovascular events as well as incident lung cancer. In his talk, Dr. Ridker will provide an update on where the field of inflammation, atherosclerosis, and cancer is going, emphasizing the importance of recognizing and treating “residual inflammatory risk”.
Learning Objectives:
At the conclusion of this session, participants will be able to:
- Understand the role of inflammation in the development of heart disease and cancer
- Understand the clinical concept of “residual inflammatory risk” and how to detect it with biomarkers
- Understand how targeting inflammation may provide a novel pathway to treat atherosclerosis and lung cancer.
Dr. Ridker serves as the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a population biology research unit at the Brigham and Womens Hospital focused primarily on translating the biology of innate immunity and vascular inflammation into clinical practice. Best known for his pioneering work on inflammatory biomarkers such as high-sensitivity CRP and interleukin-6, the first demonstrations of the anti-inflammatory effects of statins, the guideline changing JUPITER trial in 2008, and ultimately through the CANTOS interleukin-1beta inhibition trial in 2017, Dr. Ridker’s work has led to a fundamental shift in our understanding of atherosclerosis and to the first proof that targeted anti-cytokine therapies can lower cardiovascular event rates in the absence of lipid lowering. Insights from his group has led to the clinical recognition that “residual inflammatory risk” is a separate entity from “residual cholesterol risk”, and opened a novel approach to the treatment of inflammatory lung cancers. The recipient of several honorary degrees, Dr. Ridker delivered the 2018 Distinguished Scientist Lecture at the American Heart Association meetings and the 2019 Braunwald Lecture for the American College of Cardiology.